Skip to content

Cannabis and Seniors

Cannabis and Seniors

As more and more research comes out regarding the medical benefits of cannabis, it’s important to keep up with new research as it becomes available.  Here at Arfinn Med, we constantly review new studies and look at our own deidentified efficacy data to try to find any additional insights we can relay to our registered users. With that in mind, we took a closer look at research coming out of the University of Illinois and the University of Iowa regarding the medicinal benefit of cannabis on Seniors.

The research found “strong positive association” between the frequency of cannabis use by Seniors and self-reported improvements in pain, health-care utilization, and overall health-related quality of life. The researchers revealed they had “identified a strong positive association between higher frequency of cannabis use and improvement to HRQL and HCU [health-care utilization] scores.”

With many clinics seeing an increase in the amount of Seniors turning to medical cannabis, we wanted to identify some additional trends through querying our database of deidentified data for patient demographics 60 and above.

Similar to what this report indicated, we found that Seniors self-reported an average 3.7 resolution of symptoms which translates on our scale to just below a ‘significant resolution’ of symptoms. In addition to the overall efficacy, we found that chronic pain was the most frequently sited qualifying condition with both THC dominant and balanced ratios of THC and CBD being the most frequently used cannabis profiles.  Lastly, in terms of mode of consumption, tinctures were the preferred route.

If you are interested in learning more about the efficacy of medical cannabis and would like to add our electronic medical record (EMR), practice management, and telehealth platform to your practice, please schedule a quick demo by contacting info@arfinnmed.com or by clicking here!

Stories you may be interested in

Cannabis and autism, explained

Over the past decade, autistic people and their families have increasingly experimented with medical marijuana and products derived from it. Many hope these compounds will alleviate a range of autism-related traits and problems. But scientists are still in the early stages of rigorous research into marijuana’s safety and effectiveness, which means that people who pursue…
Read More

Arfinn Med Patient Site

We get a lot of interest from patients asking about efficacy data for medical marijuana on a number of conditions. Though we are primarily an electronic medical record (EMR) company focussing on the cannabis industry and other complimentary or alternative therapies, our primary focus is better quality care for patients. So with that being said,…
Read More

Are You Prepared For Questions About Medical Cannabis?

With over 85% of Americans supporting legalizing medical cannabis, it’s inevitable that patients will begin asking their primary care doctors about its use and overall efficacy. Doctors and other medical professionals will be called upon to be ‘sense-makers’ for a treatment they never studied in medical school and have limited available research to draw upon. …
Read More

Medical marijuana advocates concerned over recreational cannabis proposals

ALBUQUERQUE, N.M.— Some medical marijuana patients are concerned the proposed framework for legalizing recreational marijuana could have a potentially negative impact on the medical cannabis program. “It’s something that will devastate the medical program in doing so,” said Jason Barker, a medical cannabis advocate with Safe Access New Mexico. A special task force delivered a…
Read More

You Can Get A Master’s In Medical Cannabis In Maryland

Summer Kriegshauser is one of 150 students in the inaugural class of the University of Maryland, Baltimore’s Master of Science in Medical Cannabis Science and Therapeutics, the first graduate program of its type in the country. This will be Kriegshauser’s second master’s degree and she hopes it will offer her a chance to change careers. “I…
Read More

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More

Leave a Comment

You must be logged in to post a comment.